Use of the cathelicidin LL-37 and derivatives therof for wound healing
Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.
1. A method of stimulating proliferation of keratinocytes for cell transplantation of ulcers and burns in a patient; which comprises;
obtaining autologous human keratinocytes from a healthy skin piece excised from the patient;
transfecting the keratinocytes with a full-length hCAP18 cDNA construct; and
transplanting the transfected keratinocytes back into the patient.